Global Carcinoid Tumor Market Projected to Surpass $2.65 Billion by 2029 with 10.5% Annual Growth

What market dynamics are playing a key role in accelerating the growth of the carcinoid tumor market?
The growing obese population is expected to propel the growth of the carcinoid tumor market going forward. Obesity, characterized by a body mass index (BMI) of 30 or higher, is increasingly common due to poor dietary habits, lack of physical activity, sedentary lifestyles, and higher consumption of processed foods. Obesity contributes to the development of carcinoid tumors by promoting chronic inflammation, insulin resistance, and the increased secretion of growth factors that support tumor development. For instance, in September 2023, the Centers for Disease Control and Prevention (CDC) reported that in 2022, 22 states in the United States had an adult obesity rate of 35% or higher, up from 19 states in 2021. This rising prevalence is driving the growth of the carcinoid tumor market.

Get Your Carcinoid Tumor Market Report Here:
https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

How will the growth rate of the carcinoid tumor market shape industry trends by 2034?
The carcinoid tumor market has grown rapidly, projected to rise from $1.61 billion in 2024 to $1.78 billion in 2025 at a CAGR of 10.7%. Past market expansion was fueled by the increasing incidence of neuroendocrine tumors, greater awareness of rare cancers, advancements in healthcare infrastructure, availability of targeted therapies, and the expansion of clinical trials for new treatments.

The carcinoid tumor market is expected to witness rapid growth, reaching $2.65 billion by 2029 at a CAGR of 10.5%. Growth drivers include increasing demand for personalized medicine, heightened emphasis on early detection and diagnosis, greater adoption of minimally invasive procedures, expanded research on novel therapies, and the rising use of molecular targeted treatments. Major trends in the market include the incorporation of AI and machine learning in diagnostics, a shift toward combination therapies, the expansion of telemedicine and remote monitoring, a focus on patient-centric care, and increased collaborative research efforts.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp

What trends are poised to drive the future success of the carcinoid tumor market?
In the carcinoid tumor market, companies are enhancing diagnostic technologies to improve early detection and treatment outcomes. For instance, in October 2023, Thermo Fisher Scientific Inc., a U.S.-based biotechnology company, received FDA clearance for its B·R·A·H·M·S CgA II KRYPTOR immunoassay, the first FDA-approved automated chromogranin A (CgA) test. This test is crucial for monitoring tumor progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), helping labs and cancer centers track tumor growth and assess treatment efficacy with improved precision.

Which primary segments of the carcinoid tumor market are driving growth and industry transformations?
The carcinoid tumor market covered in this report is segmented -

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types
2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Online Channel, Offline Channel
5) By End User: Hospital And Clinics, Academic Institutions, Research Organizations

Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21127

Which geographical regions are pioneering growth in the carcinoid tumor market?
North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the influential players reshaping the carcinoid tumor market landscape?
Major companies operating in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., Dauntless Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp

What Is Covered In The Carcinoid Tumor Global Market Report?

•Market Size Forecast: Examine the carcinoid tumor market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the carcinoid tumor market for a structured understanding.
•Key Players Overview: Analyze major players in the carcinoid tumor market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the carcinoid tumor market.
•Segment Contributions: Evaluate how different segments drive overall growth in the carcinoid tumor market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the carcinoid tumor market.
•Industry Challenges: Identify potential risks and obstacles affecting the carcinoid tumor market.
•Competitive Landscape: Review strategic developments in the carcinoid tumor market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.